Unfurling the Role of Genetic Polymorphism in Rheumatic Heart Disease Pathogenesis

Shruti Sharma, Anuradha Chakraborti^*

Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

^*Corresponding author: Dr. Anuradha Chakraborti, Department of Experimental Medicine and Biotechnology

Postgraduate Institute of Medical Education and Research, Sector -12, Chandigarh – 160012, India

Received: 09 August 2021; Accepted: 17 August 2021; Published: 31 August 2021

1. Introduction

Rheumatic heart disease (RHD) is the result of an autoimmune sequelae triggered by group A streptococcus (GAS).The basic mechanism of RHD is molecular mimicry in which antigens on GAS stimulates the activation of CD4+ T cells which then cross-react with similar peptides in the heart valve tissue. According to the Global Burden of Disease (GBD) estimates, 33·4 million cases and 319 400 deaths occurred worldwide in 2015, where maximum mortality was found in low-income and middle-income countries and even in some groups living in high-income countries [1]. The GAS causes pharyngitis and if left untreated or its recurrent infection leads to the rheumatic fever (RF). It is evident that about 0.3 per cent of streptococcal sore throats result in RF and almost 90 per cent of those who get RF develop RHD [2], thus indicating the fact, that there could be influence of genetics, besides molecular mimicry [3] that might affect the development of RHD pathogenesis. However, strong evidence of factors responsible for RHD pathogenicity and the specific triggering events for RHD remain unknown. RHD is a consequence of untreated S. pyogenes mediated autoimmune reactions that leads to extreme valvular damage in genetically susceptible persons [4]. Thus, suggesting that genetic makeup of the individual also contributes in RHD. In this context, polymorphism of various genes related with RHD has also been documented. The present review highlights various genetic susceptibility factors and their role in RHD development, in-order to better understand the disease.

2. Genetic Polymorphism and RHD

The concept of involvement of genetics in RHD pathogenesis develops on the basis of observation that RHD occurs in more than one member in the family of affected person. It indicates the model of inheritance or genetic predisposition of RHD. Many gene polymorphism have been shown to be associated that includes; angiotensin converting enzyme (ACE), Human Leukocytic antigen (HLA), Interleukins (IL) like IL17, transforming growth factor (TGF) beta 1 and Mannan-binding lectin 2 (MBL) [5].

The genetic polymorphism that is most studied in the ACE gene as a marker of functional polymorphism is insertion/deletion (I/D) polymorphism which is attributed by either insertion (I) or deletion (D) of a 287-bp in the intron 16 of the ACE gene [6]. The ACE I/D polymorphism have been linked with an augmented RHD risk in different populations. Morsy et al. [5] have reported an association of DD genotype of ACE gene with the development of RHD in Egyptian children. Similarly, a study from Turkey also found RHD group with more DD genotype in comparison to control group [7]. A study from Saudi Arabia has also reported a significant association of D allele carriage with mitral valve lesion development [8]. Further, a meta-analysis including the studies from countries like India, Turkey, Taiwan and Egypt demonstrated that carriage of D allele was considerably linked with the risk of RHD occurrence [9]. On the contrary, in a Turkish study RHD group contained both II and ID genotype and control group has mainly ID genotype [10]. However, the different observations of these studies may be due to different ethnicity of the participants. Furthermore, within the country a variation in distribution of different allele among different ethnic groups was also observed [11]. These reports clearly put forward that ethnicity must be cautiously taken into consideration that associates ACE-I/D polymorphism with RHD. However, it was hypothesized that ACE I/D polymorphism is associated with RHD severity [12]. All these studies suggested the association of ACE I/D polymorphism with the progression of RHD severity, with a significant role of ACE D allele in RHD progression. Besides ACE I/D polymorphism and other genetic and environmental factors possibly may also play a significant role in RHD progression [8]. Further, ACE levels are also regulated genetically by I/D gene polymorphisms. D allele was coupled with elevated ACE level in comparison to I allele [8]. Moreover, ACE levels were found to be different in different cells and tissues i.e. elevated ACE levels were present in endothelial cells and heart valves [13]. Thus, the use of inhibitors of ACE might serve as a preventive measure in RHD.

Nevertheless, the control of immune reactions by genetic factors contribute significantly in RHD development. As, immunological responses were mainly controlled by HLA antigens, RHD has been observed to be coupled with HLA antigens [14]. Different hypothesis exists, regarding the association of risk to acquire RHD along with the HLA class II loci. Several reports from various populations have shown the association of HLA alleles with RHD. Guédez et al, [15] showed that definite class II alleles/haplotypes have revealed association with RHD risk and these links may become stronger and more consistent in clinically more homogeneous group of patients [15]. It has also been reported that certain HLA class II alleles i.e. DRB1*07-DQB1*0401-2 and DRB1*07-DQB1*0302 could be associated with the risk of occurring RHD while and certain other alleles of HLA class I i.e. DRB1*06 and DQB1*0602-8, may be protective in RHD. The genetic link between RHD susceptibility and HLA antigens were observed in Turkish patients [14]. Another study on Turkish population demonstrated that RHD susceptibility was related with HLA alleles, for example HLA DQB1*08 influence the occurrence of RHD while HLA-B51, -Cw*4 and -DRB1*01 was found to appear more in control subjects [16]. In addition, another study from same population sugg-ested another allele of HLA (HLA-DRB1*07) as genetically susceptible allele for the development of RHD while a separate allele of HLA (HLA-DRB1*11) may act as a protective allele for RHD [17]. In Indian Population, various studies especially in Kashmiri Muslim patients found that susceptibility to RHD is associated with various HLA-allels and haplotypes. According to this study, HLA-DR4 acts as susceptibility marker for RHD whereas HLA-B5 were present more common in control group [18, 19]. Further, Sreekanth et al., [20] showed HLA DRB1*15 with high RHD risk association in south Indian population. A study in south Indian population suggested the association of +3142 C/C genotype with slight risk for RHD development but it seems to add in severity of disease [21]. Another study from North Indian population showed the association of few HLA-DQB1/DRB1 alleles with RHD [22]. Thus, all these studies have indicated that these gene poly-morphism of HLA are associated with RHD.

Further, various studies have suggested that Th17 cell-associated cytokines are involved in RHD pathogenesis [23, 24]. Different gene variants of cyto-kines are majorly concerned in Th17 response that may be responsible for their differential expression in different individuals. Further, the IL 17 gene polymorphisms are related with a variety of auto-immune and inflammatory diseases development [25]. Espinoza et al. [26] demonstrated that IL17A poly-morphism at a particular position (rs2275913) also affects the expression of IL-17A. According to this study, the AA genotype that is more in RHD patients as compared to healthy control leads to increased IL17A level that consequently contributes to autoimmunity in patients with RHD [27]. In another study of animal models, cells producing IL-17- as well as IL-17 serum levels were notably elevated in rats with RHD than in control rats [24]. Further, IL17F gene polymorphism (rs763780) was also found to be significantly different between RHD patients and healthy controls [27]. Therefore, further studies focusing on expression analysis and genetic polymorphism in large cohort and in different ethnic populations are required for deeply understanding the role of Th17 in RHD pathogenesis.

Transforming growth factor-beta1 gene poly-morphism has also been observed in RHD. According to a case control study in Taiwan population, the frequency of CC genotype of TGF-1 509 polymorphism is less in RHD patients in comparison to control subjects [12]. It was also observed that this polymorphism is significantly related with the TGF-1 plasma concentration [28]. The T allele is linked with increased concentration of TGF-1, and this augmentation is more in homozygous genotype for T as compared to  heterozygotes. It suggested a dosage effect of the T allele on TGF-1 concentration [29]. Hence, suggesting the protective role of CC genotype of TGF-1 C509T polymorphism in RHD.

Gene polymorphism has also been observed in Ficolin-2 (FCN2) and MBL genes. Three ficolin (FCN) genes namely FCN1, FCN2 and FCN3 are present in humans. These produce ficolin-1, 2 & 3 [30]. It was demonstrated that FCN2 binds with several clinically important pathogens, like Streptococcus pyogenes [31]. Several studies have shown that there are various single nucleotide polymorphisms in the promoter region as well as different exons (3, 6 & 8) of the FCN2 gene [32]. Further, alteration in FCN2 serum levels was found to be associated with polymorphisms in FCN2 promoter at -602 and -4 site [33, 34]. A study from Brazalian population demonstrates that haplotype of FCN2 gene promoter affects RHD susceptibility. Another component of the lectin pathway of the complement system is Mannose-binding lectin (MBL) that plays a significant function in innate immune responses, adding in the bacterial clearance. In RHD patients, polymorphisms in MBL2 gene promoter region (-550 H/L, -221X/Y and +4P/Q) as well as in exon 1 (codons 52A/D, 54A/B and 57A/D) were studied [35]. In RHD patients, different alleles of MBL2 gene promoter and exon 1 have been observed [36]. Studies have shown that in the patients with RHD developing mitral stenosis, an association was observed with the A allele at positions (52, 54 and 57). This allele is responsible for over-expression of MBL and is also been found in the majority of patients. The genotypes that are linked with the increased formation of the MBL protein (YA/YA and YA/XA) are found to be present more in acute and chronic carditis patients as compared with the controls [37]. Conversely, O allele at 52, 54 and 57 position, which is linked with low serum levels of MBL showed association with RHD patients with aortic regurgitation [38]. Overall, it is suggested that the MBL2 gene may have an important role in valvular lesions development during RHD. In addition, this study also showed that the genotypes that lead to high serum MBL levels were linked with RHD [39]. It has been observed in several studies that the distribution of alleles, genotypes and haplotypes of MBL2 and FCN2 gene significantly vary among different populations. These variations in genetic patterns of MBL2 and FCN2 may be responsible for altered serum levels of MBL2 and FCN2and hence modulates susceptibility of disease among world populations [40].

3. Conclusion

The present review provided the information on various genetic susceptibly factors involved in the progression of RHD. Current work to elucidate other mechanisms involved in RHD are underway.

The pathogenesis of RHD is not completely known yet, so, a better understanding of RHD pathogenesis will provide the basis of early diagnosis and better treatment options in RHD in near future.

Availability of Data and Material

N/A.

Author's Contribution

SS and AC conceived the idea and designed the framework. SS, drafted the manuscript and wrote first draft. AC provided the critical comments. All authors approved the final version of the manuscript.

Code Availability

N/A.

Funding

N/A.

Compliance with Ethical Standards/Conflicts of Interest/Competing Interests

None.

Ethics Approval

N/A.

Consent to Participate

N/A.

Consent for Publication

N/A.

References

1. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. N Engl J Med 377 (2017): 713-722.
2. Kumar RK, Tandon R. Rheumatic fever & rheumatic heart disease: the last 50 years. Indian J Med Res 13 (2013): 643-658.
3. Bright PD, Mayosi BM, Martin WJ. An immunological perspective on rheumatic heart disease pathogenesis: more questions than answers. Heart 102 (2016): 1527-1532.
4. Guilherme L, Köhler KF, Postol E, Kalil J. Genes, autoimmunity and pathogenesis of rheumatic heart disease. Ann Pediatr Cardiol 4 (2011): 13-21.
5. Morsy MM, Abdelaziz NA, Boghdady AM, Ahmed H, Abu Elfadl EM, et al. Angiotensin converting enzyme DD genotype is associated with development of rheumatic heart disease in Egyptian children. Rheumatol Int 31 (2011): 17-21.
6. Pan YH, Wang M, Huang YM, et al. ACE Gene I/D Polymorphism and Obesity in 1,574 Patients with Type 2 Diabetes Mellitus. Dis Markers 2016 (2016): 7420540.
7. Atalar E, Tokgözoglu SL, Alikasifoglu M, Ovünç K, Aksöyek S, et al. Angiotensin converting enzyme genotype predicts valve damage in acute rheumatic fever. J Heart Valve Dis 12 (2003): 7-10.
8. Al-Harbi KM, Almuzaini IS, Morsy MM, Abdelaziz NA, Al-Balawi AM, et al. Angiotensin-converting enzyme gene inser-tion/deletion polymorphism in Saudi patients with rheumatic heart disease. Saudi Med J 36 (2015): 176-180.
9. Gupta U, Mishra A, Rathore SS, Agarwal SK, Pande S, et al. Association of angio-tensin I-converting enzyme gene inser-tion/deletion polymorphism with rheumatic heart disease in Indian population and meta-analysis. Mol Cell Biochem 382 (2013): 75-82.
10. Ozisik K, Emir M, Ulus AT, Kaplan S, Misirlioglu M, et al. The renin angiotensin system genetic polymorphisms and rheu-matic mitral valve disease. J Heart Valve Dis 13 (2004): 33-37.
11. Yan C, Zhan J, Feng W. Gene polymorphisms of angiotensin II type 1 rece-ptor and angiotensin-converting enzyme in two ethnic groups living in Zhejiang Pro-vince, China. J Renin Angiotensin Aldo-sterone Syst 6 (2005): 132-137.
12. Chou HT, Tsai CH, Tsai FJ. Association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and risk of rheumatic heart disease. Jpn Heart J 45 (2004): 949-957.
13. Pinto J, Viglione P, Saavedra J. Autoradiographic localization and quanti-fication of rat heart angiotensin converting enzyme. Am J Hypertens 4 (1991): 321-326.
14. Ozkan M, Carin M, Sönmez G, Senocak M, Ozdemir M, et al. HLA antigens in Turkish race with rheumatic heart disease. Circu-lation 87 (1993): 1974-1978.
15. Guédez Y, Kotby A, El-Demellawy M, Galal A, Thomson G, et al. HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Circulation 99 (1999): 2784-2790.
16. Gündogdu F, Islamoglu Y, Pirim I, Gurlertop Y, Dogan H, et al. Human leukocyte antigen (HLA) class I and II alleles in Turkish patients with rheumatic heart disease. J Heart Valve Dis 16 (2007): 293-299.
17. Haydardedeoglu FE, Tutkak H, Köse K, Düzgün N. Genetic susceptibility to rheu-matic heart disease and streptococcal phary-ngitis: association with HLA-DR alleles. Tissue Antigens 68 (2006): 293-296.
18. Bhat MS, Wani BA, Koul PA, Bisati SD, Khan MA, et al. HLA antigen pattern of Kashmiri patients with rheumatic heart disease. Indian J Med Res 105 (1997): 271-274.
19. Wani BA. Study of HLA-A, B, C, DR, DQ profile of patients with established rheumatic heart disease in Kashmir. Indian Heart J 49 (1997): 152-154.
20. Sreekanth MS, Esdan Basha SK, Arun Kumar G, Govindaraju S, Pradeep Nayar N, et al. Association of IL-1β +3953 C and HLA-DRB1*15 with Coronary Artery and Rheumatic Heart Diseases in South India. Hum Immunol 77 (2016): 1275-1279.
21. Poomarimuthu M, Elango S, Soundrapandian S, Mariakuttikan J. HLA-G 3'UTR gene polymorphisms and rheumatic heart disease: a familial study among South Indian popu-lation. Pediatr Rheumatol Online J 15 (2017): 10.
22. Toor D, Vohra H. Immune responsiveness during disease progression from acute rheu-matic fever to chronic rheumatic heart disease. Microbes Infect 14 (2012): 1111-1117.
23. Bas HD, Baser K, Yavuz E, Bolayir HA, Yaman B, et al. A shift in the balance of regulatory T and T helper 17 cells in rheu-matic heart disease. J Investig Med 62 (2014): 78-83.
24. Wen Y, Zeng Z, Gui C, et al. Changes in the expression of Th17 cell associated cytokines in the development of rheumatic heart disease. Cardiovasc Pathol 24 (2015): 382-387.
25. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 27 (2009): 485-417.
26. Espinoza JL, Takami A, Nakata K, et al. A genetic variant in the IL-17 promoter is functionally associated with acute graft versus host disease after unrelated bone marrow transplantion. PLoS One 6 (2011): 1-8.
27. Poomarimuthu M, Elango S, Solomon PR, Soundarapandian S, Mariakuttikan J. Lack of Association Between TNF-α, IFN-γ, IL-10 Gene Polymorphisms and Rheumatic Heart Disease in South Indian Population. Fetal Pediatr Pathol 37 (2018): 309-318.
28. Peng Z, Zhan L, Chen S, Xu E. Association of transforming growth factor-β1 gene C-509T and T869C polymorphisms with atherosclerotic cerebral infarction in the Chinese: a case control study. Lipids Health Dis 10 (2011): 100.
29. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, et al. Genetic control of the circulating concentration of trans-forming growth factor type beta1. Hum Mol Genet 8 (1999): 93-97.
30. Garred P, Honoré C, Ma YJ, Munthe-Fog L, Hummelshøj T. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol46 (2009): 2737-2744.
31. Lynch NJ, Roscher S, Hartung T, et al. L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J Immunol 172 (2004): 1198-1202.
32. Elshamaa MF, Hamza H, El Rahman NA, Emam S, Elghoroury EA, et al. Association of ficolin-2 (FCN2) functional poly-morphisms and protein levels with rheumatic fever and rheumatic heart disease: relation-ship with cardiac function. Arch Med Sci Atheroscler Dis 3 (2018): e142-e155.
33. Munthe-Fog L, Hummelshoj T, Hansen BE, et al. The impact of FCN2 polymorphisms and haplotypes on the ficolin- 2 serum levels. Scand J Immunol 65 (2007): 383-392.
34. Hummelshoj T, Munthe-Fog L, Madsen HO, et al. Polymorphisms in the FCN2 gene determine serum variation and function of ficolin-2. Hum Mol Genet 14 (2005): 1651-1658.
35. Luz PR, Miyazaki MI, Chiminacio Neto N, Padeski MC, Barros AC, et al. Genetically Determined MBL Deficiency Is Associated with Protection against Chronic Cardio-myopathy in Chagas Disease. PLoS Negl Trop Dis 10 (2016): e0004257.
36. Beltrame MH, Catarino SJ, Goeldner I, Boldt AB, de Messias-Reason IJ. The lectin path-way of complement and rheumatic heart disease. Front Pediatr 2 (2015): 148.
37. Schafranski MD, Pereira FL, Scherner D, et al. High-producing MBL2 genotypes incre-ase the risk of acute and chronic carditis in patients with history of rheumatic fever. Mol Immunol 45 (2008): 3827-3831.
38. Ramasawmy R, Spina GS, Faé KC, et al. Association of mannose-binding lectin gene polymorphism but not of mannose-binding serine protease 2 with chronic severe aortic regurgitation of rheumatic etiology. Clin Vaccine Immunol 15 (2008): 932-936.
39. Messias Reason IJ, Schafranski MD, Jensenius JC, et al. The association between mannose binding lectin gene polymorphism and rheumatic heart disease. Hum Immunol 67 (2006): 991-998.
40. Ojurongbe O, Ouf EA, Van Tong H, et al. Reliable and rapid characterization of functional FCN2 gene variants reveals div-erse geographical patterns. BMC Med Genet 13 (2012): 37.